Arcus Biosciences Stock Price To Earnings To Growth

RCUS Stock

USD 17.42 0.05 0.29%

Arcus Biosciences fundamentals help investors to digest information that contributes to Arcus Biosciences' financial success or failures. It also enables traders to predict the movement of Arcus Stock. The fundamental analysis module provides a way to measure Arcus Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arcus Biosciences stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Arcus Biosciences Company Price To Earnings To Growth Analysis

Arcus Biosciences' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

PEG Ratio

PE Ratio

EPS Growth

More About Price To Earnings To Growth | All Equity Analysis

Arcus Price To Earnings To Growth Driver Correlations

Understanding the fundamental principles of building solid financial models for Arcus Biosciences is extremely important. It helps to project a fair market value of Arcus Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Arcus Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arcus Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arcus Biosciences' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Capital Surpluse	Total Liab	Long Term Investments	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Deferred Long Term Liab	Net Invested Capital	Net Working Capital	Short Term Debt	Capital Stock
Total Assets		0.99	0.93	-0.21	-0.73	0.85	0.67	0.86	0.9	0.99	0.95	0.93	0.59	0.66	0.98	-0.03	0.98	0.99	0.71	0.59
Total Stockholder Equity	0.99		0.92	-0.23	-0.67	0.81	0.7	0.83	0.88	0.95	0.91	0.91	0.5	0.57	0.96	0.03	1.0	0.99	0.78	0.5
Net Tangible Assets	0.93	0.92		-0.37	-0.88	0.83	0.53	0.86	0.99	0.92	0.85	0.9	0.72	0.77	0.94	0.09	0.92	0.93	0.69	0.71
Net Debt	-0.21	-0.23	-0.37		0.58	-0.58	0.39	-0.56	-0.45	-0.2	0.05	-0.48	-0.47	-0.45	-0.38	0.14	-0.21	-0.21	-0.03	-0.47
Retained Earnings	-0.73	-0.67	-0.88	0.58		-0.82	-0.13	-0.83	-0.93	-0.76	-0.63	-0.82	-0.92	-0.94	-0.79	-0.01	-0.66	-0.69	-0.32	-0.92
Accounts Payable	0.85	0.81	0.83	-0.58	-0.82		0.2	0.98	0.86	0.86	0.7	0.97	0.74	0.75	0.92	-0.14	0.81	0.83	0.38	0.74
Net Receivables	0.67	0.7	0.53	0.39	-0.13	0.2		0.21	0.42	0.62	0.76	0.35	-0.04	0.06	0.55	-0.02	0.71	0.7	0.87	-0.05
Short Term Investments	0.86	0.83	0.86	-0.56	-0.83	0.98	0.21		0.89	0.87	0.71	0.99	0.74	0.76	0.92	0.03	0.82	0.83	0.38	0.74
Capital Surpluse	0.9	0.88	0.99	-0.45	-0.93	0.86	0.42	0.89		0.9	0.8	0.91	0.78	0.83	0.93	0.09	0.88	0.89	0.6	0.78
Total Liab	0.99	0.95	0.92	-0.2	-0.76	0.86	0.62	0.87	0.9		0.96	0.92	0.66	0.72	0.97	-0.08	0.95	0.97	0.63	0.66
Long Term Investments	0.95	0.91	0.85	0.05	-0.63	0.7	0.76	0.71	0.8	0.96		0.8	0.56	0.63	0.89	-0.08	0.92	0.93	0.66	0.56
Total Current Assets	0.93	0.91	0.9	-0.48	-0.82	0.97	0.35	0.99	0.91	0.92	0.8		0.72	0.74	0.96	-0.01	0.89	0.91	0.49	0.72
Common Stock	0.59	0.5	0.72	-0.47	-0.92	0.74	-0.04	0.74	0.78	0.66	0.56	0.72		0.99	0.65	-0.12	0.51	0.55	0.03	1.0
Property Plant Equipment	0.66	0.57	0.77	-0.45	-0.94	0.75	0.06	0.76	0.83	0.72	0.63	0.74	0.99		0.7	-0.12	0.58	0.61	0.12	0.99
Current Deferred Revenue	0.98	0.96	0.94	-0.38	-0.79	0.92	0.55	0.92	0.93	0.97	0.89	0.96	0.65	0.7		-0.11	0.96	0.97	0.67	0.65
Deferred Long Term Liab	-0.03	0.03	0.09	0.14	-0.01	-0.14	-0.02	0.03	0.09	-0.08	-0.08	-0.01	-0.12	-0.12	-0.11		-0.03	-0.06	0.05	-0.13
Net Invested Capital	0.98	1.0	0.92	-0.21	-0.66	0.81	0.71	0.82	0.88	0.95	0.92	0.89	0.51	0.58	0.96	-0.03		1.0	0.79	0.51
Net Working Capital	0.99	0.99	0.93	-0.21	-0.69	0.83	0.7	0.83	0.89	0.97	0.93	0.91	0.55	0.61	0.97	-0.06	1.0		0.76	0.55
Short Term Debt	0.71	0.78	0.69	-0.03	-0.32	0.38	0.87	0.38	0.6	0.63	0.66	0.49	0.03	0.12	0.67	0.05	0.79	0.76		0.03
Capital Stock	0.59	0.5	0.71	-0.47	-0.92	0.74	-0.05	0.74	0.78	0.66	0.56	0.72	1.0	0.99	0.65	-0.13	0.51	0.55	0.03

Click cells to compare fundamentals

Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.

Competition

Predict Arcus Biosciences

Arcus Price Earnings To Growth Ratio

Price Earnings To Growth Ratio

(0.41)

At this time, Arcus Biosciences' Price Earnings To Growth Ratio is comparatively stable compared to the past year.

Based on the latest financial disclosure, Arcus Biosciences has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.

Arcus Price To Earnings To Growth Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arcus Biosciences' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arcus Biosciences could also be used in its relative valuation, which is a method of valuing Arcus Biosciences by comparing valuation metrics of similar companies.

Arcus Biosciences is currently under evaluation in price to earnings to growth category among its peers.

Arcus Biosciences ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arcus Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arcus Biosciences' managers, analysts, and investors.

Environmental

Governance

Social

Arcus Fundamentals

	Return On Equity	-0.5
	Return On Asset	-0.15
	Profit Margin	(1.03) %
	Operating Margin	(2.19) %
	Current Valuation	612.55 M
	Shares Outstanding	91.51 M
	Shares Owned By Insiders	40.60 %
	Shares Owned By Institutions	60.10 %
	Number Of Shares Shorted	8.03 M
	Price To Earning	27.69 X
	Price To Book	2.91 X
	Price To Sales	6.25 X
	Revenue	117 M
	Gross Profit	(176 M)
	EBITDA	(283 M)
	Net Income	(307 M)
	Cash And Equivalents	1.05 B
	Cash Per Share	14.48 X
	Total Debt	11 M
	Debt To Equity	0.17 %
	Current Ratio	6.22 X
	Book Value Per Share	6.17 X
	Cash Flow From Operations	(306 M)
	Short Ratio	10.60 X
	Earnings Per Share	(3.19) X
	Target Price	33.2
	Number Of Employees	577
	Beta	0.89
	Market Capitalization	1.64 B
	Total Asset	1.09 B
	Retained Earnings	(849 M)
	Working Capital	647 M
	Net Asset	1.09 B

About Arcus Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Arcus Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcus Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcus Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Arcus Stock Analysis

When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC